- In October 2021, the National Institute of Allergy and Infectious Diseases (NIAID) launched a study on primary prophylaxis for cerebral toxoplasmosis in HIV-infected patients. Participants are administered pyrimethamine or a placebo, alongside leucovorin calcium, three times a week for approximately 12 months. The study aims to follow patients for up to three years, with a final analysis based on the common study close-out date, assessing the effectiveness of the treatment regimen in preventing toxoplasmosis in this high-risk population
- In March 2020, Dr. Reddy's Laboratories launched Pyrimethamine Tablets USP, 25 mg, as the first generic equivalent to Daraprim (pyrimethamine), approved by the U.S. Food and Drug Administration (FDA). This product is the only AB-rated generic version of Daraprim authorized by the FDA. Pyrimethamine is used in combination with a sulfonamide to treat toxoplasmosis, as the two drugs work synergistically to combat the infection effectively
